- The study investigated cannabidiol (CBD) effects on pain modulation, craving, and cognition in patients with opioid use disorder and chronic pain receiving opioid agonist treatment.
- This randomized, double-blind, placebo-controlled crossover study included 23 participants receiving methadone, evaluating acute oral CBD doses (400, 800, 1200 mg).
- Pre-opioid agonist treatment, CBD showed a linear dose-response for enhanced descending pain inhibition (p = 0.034), with effect sizes of d'=0.34 at 800 mg and d'=0.59 at 1200 mg.
- The authors concluded that CBD's effects on pain modulation are phase-dependent, with benefits pre-opioid agonist treatment but worsened pain sensitivity post-treatment at higher doses.
- These findings suggest that the timing of opioid agonist treatment administration is a critical factor for CBD-based pain interventions in this patient population.
Navigating Chronic Pain and Opioid Use Disorder: The Role of Cannabidiol
Chronic pain and opioid use disorder (OUD) frequently co-occur, creating a complex clinical challenge for physicians, especially when patients are stabilized on opioid agonist treatment (OAT) [1]. Despite the efficacy of OAT for managing OUD, chronic pain often persists, partly because exogenous opioids can impair the body's endogenous pain modulation systems [1]. This has spurred a search for effective, non-opioid adjunctive therapies. Cannabidiol (CBD), a non-intoxicating cannabinoid, has been a compound of interest due to its potential analgesic and anxiolytic properties [2, 3, 4]. While some studies have explored its use for OUD or chronic pain separately [5, 6, 7, 8], its specific effects in patients simultaneously managing both conditions while on OAT have remained largely unknown, with prior systematic reviews noting a lack of high-quality evidence [9, 10]. This knowledge gap highlights the need for precise data to guide clinicians on CBD's potential role in this vulnerable patient group.
Study Design and Participant Characteristics
To address this clinical question, investigators conducted a randomized, double-blind, placebo-controlled crossover study, a rigorous design where each participant serves as their own control. The trial evaluated the acute effects of oral cannabidiol (CBD) at three distinct doses: 400 mg, 800 mg, and 1200 mg. The study enrolled 23 participants, 11 of whom were female, all with co-occurring opioid use disorder (OUD) and chronic pain. All were actively receiving methadone as part of their opioid agonist treatment (OAT), with a mean daily dose of 85.7 mg (SD: 29.7 mg), reflecting a typical cohort in clinical practice.
A key feature of the study was an opioid withholding model designed to assess CBD's effects during two distinct physiological states. The Pre-OAT phase involved administering CBD after a delayed methadone dose, while the Post-OAT phase involved CBD administration following the participant's regular daily methadone dose. The primary outcomes focused on objective measures of pain processing, assessed via quantitative sensory testing, a method that uses calibrated thermal stimuli to precisely measure pain perception. These outcomes included conditioned pain modulation (CPM), which measures the central nervous system's ability to inhibit pain signals from the periphery in a top-down manner, and temporal summation of pain (TSP), which reflects the amplification of pain signals within the spinal cord, a process known as ascending facilitation. Secondary outcomes included heat pain threshold and tolerance, with exploratory measures of cue-induced craving and cognitive performance.
Phase-Dependent Effects on Pain Modulation
The study's central finding is that cannabidiol's (CBD) effect on pain processing is highly dependent on the timing of its administration relative to a patient's daily methadone dose. During the Pre-OAT phase, when methadone was withheld, CBD appeared to bolster the body's innate pain-dampening mechanisms. The researchers found CBD was associated with a significant linear dose-response for enhanced descending pain inhibition (p = 0.034). This effect, measured as conditioned pain modulation, reflects an improved ability of the brain to suppress incoming pain signals. The effect was dose-dependent, with a modest effect size at 800 mg (d'=0.34) and a more substantial one at the 1200 mg dose (d'=0.59).
In stark contrast, the effects reversed after participants received their daily methadone. In this Post-OAT phase, the highest dose of CBD had a detrimental effect on pain sensitivity. Specifically, CBD at 1200 mg was associated with a significant reduction of the heat pain threshold compared to placebo (d'=-0.63, p = 0.017). A lower heat pain threshold indicates that participants perceived a stimulus as painful at a lower temperature, signifying a state of hyperalgesia or worsened pain sensitivity. Taken together, these results reveal a complex interaction: CBD appears to enhance the body's own pain control systems when administered before the daily opioid agonist, but may paradoxically increase pain sensitivity at high doses when administered after.
Impact on Craving, Cognition, and Safety Profile
Beyond its complex effects on pain, the study evaluated cannabidiol's (CBD) influence on other outcomes critical to managing patients with opioid use disorder (OUD). Investigators found that CBD showed no significant effects on opioid craving, an important exploratory outcome. This finding suggests that, at the doses tested, CBD did not appear to directly blunt the psychological drive for opioids in this patient group. From a safety perspective, the study also assessed cognitive function, a key concern when adding central nervous system active agents to a methadone regimen. Reassuringly, cognitive performance was preserved across all tested CBD doses (400 mg, 800 mg, and 1200 mg). Overall, the researchers concluded that CBD demonstrated a favorable safety profile, as the acute doses were well-tolerated without significant adverse events. The absence of cognitive impairment or an impact on craving provides crucial context for evaluating the clinical utility of CBD as an adjunctive therapy.
Clinical Implications for Adjunctive Pain Management
These findings provide crucial, albeit complex, guidance for clinicians considering cannabidiol (CBD) for patients on opioid agonist treatment (OAT) with comorbid chronic pain. The study's primary takeaway is that the timing of CBD administration relative to the daily methadone dose is not a minor detail but a critical determinant of its effect. The data suggest a potential therapeutic window for CBD's beneficial effects on pain modulation. Administering CBD before the daily OAT dose may leverage its ability to enhance descending pain inhibition, potentially helping to restore the body's own blunted pain-control mechanisms. This was demonstrated by the significant linear dose-response for enhanced descending pain inhibition in the Pre-OAT phase (p = 0.034).
Conversely, clinicians should exercise caution with high-dose CBD administered after the daily OAT dose. The finding that 1200 mg of CBD significantly reduced the heat pain threshold post-methadone (p = 0.017) suggests a risk of paradoxically increasing pain sensitivity. While CBD was found to be safe and did not impact cognition or craving, its utility for pain in this population appears to be highly context-dependent. These results underscore that OAT timing is a critical factor to consider in the design of future trials and in any potential clinical application of CBD for pain management in patients with OUD.
References
1. Costa GPA, Sofuoglu M, Compton P, Ranganathan M, Pittman B, Aquino JPD. An opioid-withholding human laboratory paradigm during opioid agonist treatment for opioid use disorder and chronic pain: Phase- and dose-dependent effects of cannabidiol.. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2026. doi:10.1038/s41386-026-02443-w
2. Wang L, Hong PJ, May C, et al. Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials. BMJ. 2021. doi:10.1136/bmj.n1034
3. Shafie M, Ing K, Rostam-Abadi Y, et al. The Potential Use of Cannabidiol in the Treatment of Opioid Use Disorder: A Systematic Review.. Addiction biology. 2025. doi:10.1111/adb.70047
4. Paulus V, Billieux J, Benyamina A, Karila L. Cannabidiol in the context of substance use disorder treatment: A systematic review.. Addictive Behaviours. 2022. doi:10.1016/j.addbeh.2022.107360
5. Lynch M, Campbell F. Cannabinoids for treatment of chronic non‐cancer pain; a systematic review of randomized trials. British Journal of Clinical Pharmacology. 2011. doi:10.1111/j.1365-2125.2011.03970.x
6. Suzuki J, Prostko S, Szpak V, et al. Impact of cannabidiol on reward- and stress-related neurocognitive processes among individuals with opioid use disorder: A pilot, double-blind, placebo-controlled, randomized cross-over trial.. Frontiers in psychiatry. 2023. doi:10.3389/fpsyt.2023.1155984
7. London ED, Dean AC, Garza RDL, et al. Adjunctive Cannabidiol in Inpatient Buprenorphine Treatment for Opioid Use Disorder: A Pilot Randomized Trial.. Journal of addiction medicine. 2025. doi:10.1097/ADM.0000000000001640
8. Chou R, Ahmed AY, Dana T, et al. Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2024 Update. 2024. doi:10.23970/ahrqepccer250.2024update
9. Fisher E, Moore A, Fogarty AE, et al. Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials. Pain. 2020. doi:10.1097/j.pain.0000000000001929
10. Boehnke K, Clauw D. Cannabinoids for Chronic Pain: Translating Systematic Review Findings Into Clinical Action. Annals of Internal Medicine. 2022. doi:10.7326/M22-1512